Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synovial macrophage-targeted hierarchical microspheres achieve cartilage preservation and pain relief in osteoarthritis.

Materials today. Bio·2026
Same author

Clinical profiling and outcomes of ischaemic stroke patients with immune thrombocytopenia: A multicentre retrospective study.

British journal of haematology·2026
Same author

RORα: a critical nexus in the crosstalk between cholesterol metabolism and macrophage polarization.

Frontiers in immunology·2026
Same author

Both of coagulopathy and neutrophil extracellular trap markers are associated with poor prognosis of dabie bandavirus infection.

Clinica chimica acta; international journal of clinical chemistry·2026
Same author

Correction to: Significance of targeting DNMT3A mutations in AML.

Annals of hematology·2026
Same author

TNFRSF13B Variant-Induced TACI Dysregulation Underlies CAEBV Pathogenesis.

Journal of clinical immunology·2026

Related Experiment Video

Updated: Sep 10, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K

Improving CAR-T cell function through a targeted cytokine delivery system utilizing car target-modified extracellular

Yuanyuan Zhang1,2, Meijuan Huang1,2, Shujia Zhang1,2

  • 1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Experimental Hematology & Oncology
|August 26, 2025
PubMed
Summary

This study introduces extracellular vesicles (EVs) engineered to deliver interleukin-12 (IL-12) directly to chimeric antigen receptor (CAR)-T cells, enhancing their cancer-fighting ability and reducing systemic toxicity for improved CAR-T-cell therapy.

Keywords:
Cellular immunotherapyChimeric antigen receptor T cellExtracellular vesiclesInterleukin-12

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

791
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

431

Related Experiment Videos

Last Updated: Sep 10, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

791
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

431

Area of Science:

  • Immunotherapy
  • Cell Biology
  • Nanotechnology

Background:

  • Chimeric antigen receptor (CAR)-T-cell therapy shows promise for B-cell malignancies but faces challenges with T-cell persistence and efficacy.
  • Systemic administration of interleukin-12 (IL-12), a potent immunotherapy agent, is limited by severe toxicity.

Purpose of the Study:

  • To develop a novel extracellular vesicle (EV)-based delivery system for targeted IL-12 delivery to CAR-T cells.
  • To enhance CAR-T-cell function and antitumor activity while mitigating IL-12-associated toxicity.

Main Methods:

  • Engineered HEK-293T cells to produce EVs displaying CD19 and/or IL-12.
  • Assessed the in vitro efficacy of IL-12 EVs and CD19/IL-12 EVs on anti-CD19 CAR-T cells.
  • Evaluated the in vivo antitumor response and CAR-T-cell expansion in a xenograft mouse model.

Main Results:

  • IL-12 EVs significantly boosted CAR-T-cell effector functions (IFN-γ, TNF-α secretion, cytotoxicity, expansion) in vitro.
  • CD19/IL-12 EVs demonstrated superior binding to CAR-T cells compared to IL-12 EVs alone.
  • Intratumoral administration of CD19/IL-12 EVs in mice led to durable antitumor responses and enhanced CAR-T-cell expansion without systemic toxicity.

Conclusions:

  • CAR-targeted EVs serve as an effective platform for localized IL-12 delivery to augment CAR-T-cell function.
  • This approach offers a safer and more potent strategy for enhancing CAR-T-cell immunotherapy in B-cell malignancies.